Luzitin attends the BIO International Convention 2016, in San Francisco, CA (US)

2016-05-30 in Press Release Luzitin

From the 6th to 9th June, Luzitin will attend the world’s largest biotechnology network event, BIO International Convention 2016, in San Francisco, California (US). The company is offering innovative therapeutic solutions for cancer therapy.

Luzitin’s most advanced project consists of a combination of a proprietary new generation photosensitiser, Redaporfin (LUZ11), followed by its local activation in the tumour mass in a targeted manner, with a light of appropriate wavelength.

At this years’ edition of BIO, Luzitin will be seeking for strategic partners in order to further its technology development. Redaporfin (LUZ11) is currently concluding its Proof-of-concept (POC) clinical trials in humans with promising results. In addition, Luzitin was granted from EMA an orphan drug designation for the treatment of Biliary Tract Cancer and a clear and well-defined development plan was drawn up by Luzitin’s experienced management, scientific and technical team. Aiming the worldwide market, Luzitin looks for pharmaceutical and investment companies for onward development and commercialisation of Redaporfin (LUZ11), from Proof-of-concept (POC) in humans until Marketing Authorisation (MA).

 

About Luzitin


Luzitin focuses on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT).

For decades PDT to treat cancer has held great promise due to its ability to selectively destroy tumours accessible to light along with the absence of harmful long term side effects often encountered with chemotherapy or radiotherapy.

However, technological limitations of current marketed products have heretofore prevented PDT from reaching its full potential. Luzitin has developed a new photosensitizer compound, Redaporfin™, which promises to bring PDT to routine daily practice for treatment of solid tumours.

Redaporfin (LUZ11) goes beyond PDT’s traditional approach, being a patented, third generation photosensitizer compound which was specifically designed to overcome the pitfalls of the marketed photosensitizers of systemic administration for cancer (i.e. porfimer sodium - Photofrin®, and temoporfin - Foscan®).

 

About BIO International Convention


The BIO International Convention is the world’s largest biotechnology network gathering and covers a wide spectrum of life science and application areas including novel therapeutics in the oncology field. The event counts with more than 1,700 exhibitors and is attended by 15,000+ biotechnology and pharma leaders, pursuing partnering opportunities and aiming to discover new players in the industry, as well as emerging technologies.

For more information visit the official conference website here.



Bluepharma
Bluepharma
Bluepharma
Bluepharma
Bluepharma
Bluepharma